The Hematological Malignancy program consists of a multidisciplinary team focused on the prevention, diagnosis, and treatment of cancers arising in the bone marrow, lymph nodes and other associated hematological organs. Overall the program is equipped to design and deliver customized and personalized therapy for each child and adolescent in the cancer center diagnosed with a hematological malignancy.
The Blood and Marrow Transplantation (BMT) Program consists of a multidisciplinary team dedicated to the therapeutic use of bone marrow, peripheral blood, cord blood and cellular therapy in the treatment of children, adolescents and young adults with malignant, non-malignant, and serious blood-related disorders.
The Developmental and Experimental Therapeutics program is focused on the translational and clinical application of new therapeutic strategies in early phase experimental clinical investigation. This program is designed to determine the safety, feasibility, dose, schedule and early efficacy of new therapeutic strategies during experimental clinical investigation in children, adolescents and young adults with both malignant and non-malignant (blood disease-related) disorders.
The Cellular and Tissue Engineering Laboratory (CTEL) within the Children and Adolescent Cancer & Blood Disease Center at Maria Fareri Children’s Hospital consists of a "good manufacturing practice” (cGMP) facility. But this manufacturing “plant” doesn’t turn out cars, pens, candies, clips or anything that can be seen with the naked eye. Instead, it creates the defining feature of medicine’s new frontier: human cells. The state-of-the-art equipment in the CTEL is designed to facilitate cellular therapy (CT) under investigational new drug applications (IND), in support of cellular therapy that will treat a variety of disorders and diseases. With a focus on oncology, hematology, neurology, genetics and cardiovascular therapies, the CTEL supports a range of translational programs that harness stem cell, cellular, tissue and gene therapies. The research team has FDA approval for several clinical protocols to treat some cancer, genetic and blood diseases.
Patient and Family Support is one of the most important parts of our Mission at CCF. A cancer diagnosis is a life-changing event, especially in the pediatric population. Understanding and identifying risks for psychosocial adjustment difficulties within families of children with cancer is very complex. Social workers and Psychosocial support staff play a valuable and unique role in assessing and implementing interventions that assist patients and their families to cope with illness. This aspect of patient care is so important to CCF that for 20 years, CCF supported the salary of the two licensed, clinical social workers within the division. Currently, CCF also funds a full-time Psychologist that works closely with the Social Workers. Together they provide in-patient and out-patient care affording the patient/family to have a consistent presence to guide them through their ordeal.